Heart Fail Clin 2022 Jul 1;18(3):425-442. Epub 2022 Jun 1.
Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University College of Medicine, Columbus, OH 43210, USA; Division of Cardiology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA. Electronic address:
Tyrosine kinase inhibitors (TKIs) are used to treat several cancers; however, a myriad of adverse cardiotoxic effects remain a primary concern. Although hypertension (HTN) is the most common adverse effect reported with TKI therapy, incidents of arrhythmias (eg, QT prolongation, atrial fibrillation) and heart failure are also prevalent. These complications warrant further research toward understanding the mechanisms of TKI-induced cardiotoxicity. Read More